



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

**PRESS RELEASE**

**Noida, Thursday, June 30, 2022**

**Jubilant HollisterStier announces CAD 100 Mn expansion of its CMO manufacturing facility at Montreal, Canada and Government of Quebec funding of CAD 25 Mn through a loan**

Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, through one of its wholly owned subsidiaries, Jubilant HollisterStier General Partnership, (JHS) a leading Canada-based pharmaceutical contract manufacturer, announced today that the Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million, which includes a forgivable portion of CAD 6.3 million to fund the CAD 100 Mn capacity expansion at the CMO Montreal facility. The loan disbursement is subject to final agreement to be signed between the two parties.

This investment aims to modernize and augment the drug production capacity by over 100% at the Montreal, Canada facility. As part of this initiative, Jubilant HollisterStier will acquire new specialized equipment and equip the plant with a single-use sterile preparation room to maximize the filling process linked to the production of liquid sterile products.

The Minister of Economy and Innovation and Minister responsible for Regional Economic Development, Mr. Pierre Fitzgibbon, made the announcement today.

"This modernization project shows the effervescence that is being created in Montreal in the life sciences. To have a more efficient health network, we must increase our health autonomy. The pandemic has shown us how important it is to strengthen our supply chains, and that is exactly what we are doing today." **said Mr Pierre Fitzgibbon.**

**Christian Dubé, Minister of Health and Social Services said,** "Quebec has a strong industrial fabric in life sciences, and the modernization of Jubilant HollisterStier's facilities will further consolidate this key sector. This project will also generate contract development and manufacturing activities for other Quebec biopharmaceutical companies. With the new Québec Life Sciences Strategy, we want to create even more synergies like this between our companies to meet the major health challenges."

**Speaking on the announcement, Mr Pramod Yadav, CEO, Jubilant Pharma Limited said,** "Jubilant HollisterStier is excited to be chosen as a part of the eco-system being developed by Canada to make it self-dependent for its future needs of vaccines and treatments in case of a pandemic. This funding will enable our continued effort to expand our capabilities in Canada and create more jobs."

"This new agreement is a testament to the contributions of our organization during the current pandemic and public health emergencies over the past two decades. Jubilant HollisterStier's expansion will target large Pharmaceuticals and Biotech companies parenteral products as well as feature a flexible manufacturing platform able to produce several types of vaccines (live, mRNA and inactivated/subunit).," **shared Mr Amit Arora, President, Contract Manufacturing Organization (CMO), Jubilant HollisterStier.**

---



### **About Jubilant HollisterStier**

Jubilant HollisterStier, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full range of support to streamline manufacturing, from process qualifications through commercial release. For more info please visit [www.jublhs.com](http://www.jublhs.com)

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of over 4,600 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more info please visit [www.jubilantpharma.com](http://www.jubilantpharma.com)

### **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

### **Government Fund**

Launched on May 12, the 2022-2025 Québec Life Sciences Strategy aims in particular to support the creation and growth of innovative companies, to attract and materialize investment projects and to stimulate the commercialization of innovations. . To reach his objectives, it has an envelope of \$211 million (Canadian Dollars), which will generate investments of nearly \$2 billion over the next three years.

---



Ministry of Economy and Innovation on social networks:

- [twitter.com/economie\\_quebec](https://twitter.com/economie_quebec)
- [facebook.com/EconomieQc](https://facebook.com/EconomieQc)
- [linkedin.com/company/economy-quebec](https://linkedin.com/company/economy-quebec)
- [youtube.com/c/ÉconomieQuébec](https://youtube.com/c/ÉconomieQuébec)
- [instagram.com/economieqc](https://instagram.com/economieqc)

Sources:

Mathieu St-Amand  
Communications Director  
Office of the Minister of the Economy  
and Innovation and Minister Responsible  
Regional Economic Development  
Such. : 418 691-5650

Marjaurie Cote-Boileau  
Press Officer  
Office of the Minister of Health  
and Social Services  
Such. : 418 456-2756

Information :  
Jean-Pierre D'Auteuil  
Media Relations Manager  
Communications Branch  
Ministry of Economy and Innovation  
Such. : 418 691-5698, extension 4868 Cell. : 418 559-0710

**For more information, please contact:**

**For Investors**

**Vineet V Mayer**

Ph: +91 120 436 1103

E-mail: [vineet.mayer@jubl.com](mailto:vineet.mayer@jubl.com)

### ***Disclaimer***

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

---